Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

AbbVie, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.

Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 76.2 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (10.1 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.02) at month six.

Картинки по запросу elagolix

Uterine fibroids are the most common type of abnormal growth in a woman's pelvis and can affect up to 80 percent of women by age 50. Fibroids can be asymptomatic, but in approximately 25 percent of women, fibroids can cause symptoms, such as heavy menstrual bleeding, painful periods, vaginal bleeding at times other than menstruation, and anemia. African American women are more likely to experience fibroids and do so at a younger age.

"Millions of women currently diagnosed with uterine fibroids are faced with limited non-surgical options," said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. "The results from this study demonstrate elagolix has the potential to be an important oral treatment option for women suffering from uterine fibroids."

Hypoestrogenic effects, such as hot flush and reduction in bone mineral density, from elagolix treatment were observed in the study. The overall safety profile for elagolix was consistent with what was observed in Phase 2 studies and the first Phase 3 study (ELARIS UF-I) in uterine fibroids.1,5-6 Data from the ELARIS UF-II Phase 3 study will support regulatory submissions for elagolix. Safety data, including most common adverse events, continue to be collected in this ongoing study.

The topline results from this six-month primary analysis were consistent with topline results from the ELARIS UF-I study reported in February 2018 and will be presented at an upcoming medical conference. Women in the study will continue in either post-treatment follow-up or a blinded six-month extension study.

About Study Design

ELARIS UF-II is the second of two replicate, pivotal, six-month Phase 3 studies evaluating the safety, tolerability and efficacy of elagolix alone (300 mg twice daily) and in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), in women with uterine fibroids.  Study participants were premenopausal women, age 18–51 years old, with a diagnosis of uterine fibroids documented by a pelvic transvaginal and transabdominal ultrasound (TAU, TVU).  The primary endpoint assessed the reduction in heavy menstrual bleeding compared to placebo as measured by the alkaline hematin method, an objective measurement of total menstrual blood loss based on quantitation of menstrual blood collected on sanitary products. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The ranked secondary endpoints included measures of bleeding, bleeding suppression and hemoglobin changes. The study was conducted at approximately 100 sites in the United States and Canada.

Wed, 03/14/2018

https://www.dddmag.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company